HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Reverse-Switches Muscle Relaxant Methocarbamol

Executive Summary

French regulator ANSM's response to reports of seizures triggered by muscle relaxant methocarbamol is to reverse-switch the drug from OTC-to-Rx status.

You may also be interested in...



Government Skepticism And Over Regulation Holding Back Self-Care In France – GSCF Analysis

France's self-medication market lags behind its European rivals. Why is that? A skeptical and over-cautious government and a stifling regulatory system may provide at least part of the answer, the Global Self-Care Federation's recently published Self-Care Readiness Index suggests.  

France ‘Not Receptive’ To Self-Care, But Wellness And E-Commerce Trends Are Driving Change

Regulatory barriers, government conservativism and a generous reimbursement system have all held back the development of France's self-care market. However, executive director of the French self-care industry association, Luc Besançon, thinks that the growing trends for prevention and e-commerce will change this in the future. 

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel